GAMRIF

CARB-X published compulsory guidance on Monday to ensure that new antibacterial products brought to market by its funded companies are used responsibly and made available to people in LMICs.

The Stewardship and Access Plan Development Guide—created by the Boston University-led nonprofit and its partners, including the Access to Medicine Foundation, the Gates Foundation, the Global Antibiotic Research and Development Partnership, the Global Antimicrobial Resistance Innovation Fund, and…

CARB-X announced this week up to $10.9 million for the University of Queensland’s Institute for Molecular Bioscience to develop a new class of safer antibiotics to replace last-resort polymyxin-class drugs, such as colistin.

CARB-X is also giving an additional $4.6 million to boost an investigational new drug submission for previous grantee Amicrobe’s Amicidin-β topical solution aimed at surgical and traumatic wound infections—and for a new formulation of the product for infection…